Quanterix (Nasdaq:QTRX) announced today that it received FDA breakthrough device designation for a multiple sclerosis (MS) diagnostic. Billerica, Massachusetts-based Quanterix designed its Simoa neurofilament light chain (NfL) plasma test as a prognostic aid in assessing the risk of disease activity in patients diagnosed with relapsing-remitting MS (RRMS). According to a news release, the company designed […]
Quanterix Corp.
Quanterix appoints chief operating officer
Quanterix (NSDQ:QTRX) this week said it appointed William Geist as chief operating officer, effective Nov. 16. Geist has more than 25 years of experience and most recently served as VP and general manager for Thermo Fisher Scientific’s protein and cell analysis and qPCR business units. He also held numerous sales, marketing and business development leadership roles […]
NIH announces more than $98M in contracts for new COVID-19 testing tech
The National Institutes of Health today announced six new contracts worth $98.35 million for COVID-19 testing approaches to improve sample collection, processing and results. NIH awarded the contracts in collaboration with the Biomedical Advanced Research and Development Authority (BARDA) as part of the Rapid Acceleration of Diagnostics (RADx) initiative. They cover innovations including integration with […]
Quanterix, Abbott sign licensing agreement
Quanterix announced (NSDQ:QTRX) announced that it entered into a licensing agreement with Abbott (NYSE:ABT). Billerica, Mass.-based Quanterix’s agreement with Abbott is a non-exclusive, royalty-bearing license agreement that grants Abbott access to Quanterix’s portfolio of bead-based technology patents for use with in vitro diagnostic applications, according to a news release. Under the terms of the agreement, Quanterix will […]
Quanterix prices $84.8M public offering
Quanterix announced (NSDQ:QTRX) announced that it priced its previously announced underwritten public offering of common stock at $32 per share. Billerica, Mass.-based Quanterix is selling 2,651,108 shares of its common stock and expects to collect gross proceeds of approximately $84.8 million. Quanterix also granted underwriters a 30-day option to purchase up to 397,666 additional shares […]
Quanterix prices IPO common stock at $60m
Quanterix today announced an initial public offering of nearly 2.4 million shares of common stock at $25.25 apiece for which it expects to gross $60 million. Billerica, Mass.-based Quanterix is developing a digital approach to immunoassays to allow single molecules to be counted. Its technology is used in the therapeutic areas of oncology, neurology, cardiology, […]
Ex-Millipore CEO Madaus steps down from Covidien board
Covidien taps Quanterix CEO for board | Personnel Moves
Med-tech titan Covidien (NYSE:COV) named Quanterix Corp. CEO Martin Madaus to its board of directors.
Madaus, the former head of Millipore, was tapped by Quanterix in September for the corner office. His nomination, effective Dec. 1, is slated for a shareholder vote next year.
Intrinsic Therapeutics puts a new man in charge | Personnel Moves
Intrinsic Therapeutics named Wright Medical (NSQD:WMGI) veteran Cary Hagan as its new President & CEO. Greg Lambrect, founder of Intrinsic will stay on as executive director.
"Cary’s proven success in bringing new technologies to the global market makes him an ideal choice to lead Intrinsic’s next stage of growth as we expand our international clinical and commercial activity," said Lambrecht in prepared remarks.
Dr. Martin Madaus joins Quanterix as CEO
Former CEO of Millipore Brings Extensive Commercial Expertise to New Role
Tissue Genesis starts trial on vascular grafts with fat-derived stem cells | Research roundup
Tissue Genesis Inc. began clinical trials for a peripheral vascular disease (PVD) treatment composed of adipose-derived adult stem cell-coated vascular grafts. Adipose is more commonly know as fat, a tissue that the company believes has high-output regenerative medicine potential.
The Honolulu-based Tissue Genesis is the first to initiate an FDA-approved trial using the patient’s own fat-derived adult stem cells (ASCs) prepared at the point-of-care, according the company company.
